Physician profile
Kyle W Moore
NPI 1942778386
$2,036.01
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $656 · 2022: $1,000 · 2023: $355 · 2024: $24.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $687.93 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $288.83 | 2021-2023 | Farxiga |
| Glaxosmithkline, LLC. | $166.07 | 2021-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $135.38 | 2021-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $130.53 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $110.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.23 | 2022 | |
| Pfizer INC. | $52.20 | 2021-2022 | |
| Amgen INC. | $49.23 | 2022-2024 | Repatha, Otezla |
| Lilly USA, LLC | $46.44 | 2021-2022 | |
| Novo Nordisk INC | $43.96 | 2022-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $31.48 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceuticals, INC. | $28.57 | 2021 | |
| Currax Pharmaceuticals LLC | $27.03 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $20.02 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $19.27 | 2022 | |
| Seqirus USA INC | $19.00 | 2022 | |
| Daiichi Sankyo INC. | $18.32 | 2023 | Injectafer |
| Sunovion Pharmaceuticals INC. | $18.13 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.49 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.19 | 2023 | Edarbyclor |
| Kowa Pharmaceuticals America, INC. | $13.71 | 2021 | |
| Grifols USA, LLC | $12.74 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.